News
Amryt’s Myalepta scores NICE backing for rare lipid disorder
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Amryt Pharma’s Myalepta (metreleptin) for use within the NHS.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Amryt Pharma’s Myalepta (metreleptin) for use within the NHS.